NCM · Biotechnology

Moolec Science SA (MLEC) Stock

$2.60 -37.95% NCM: MLEC Healthcare

Valuation

MetricValue
Price$2.60
Market Cap$1.89M
P/E Ratio-0.02
P/B Ratio-0.03
P/S Ratio0.01
EPS (TTM)$-258.75
52-Week High$23.22
52-Week Low$2.60
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE376.84%
ROA-54.45%
ROCE33.43%
Gross Margin-2.99%
Operating Margin-2.99%
Net Margin-33.41%
Debt/Equity-3.74
Current Ratio0.13

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$1.0M$6.0M$334.0M
Operating Profit$0$-2.0M$-7.0M$-9.0M$-10.0M
Net Profit$0$-5.0M$-52.0M$-7.0M$-111.0M
EPS$-0.01$-1.80$-22.50$-2.85$-258.75
Op Margin——-735.2%-160.8%-3.1%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$139.0M$6.0M$24.0M$35.0M$205.0M
Total Liabilities$5.0M$4.0M$14.0M$28.0M$288.0M
Cash$0$1.0M$3.0M$5.0M$1.0M
Borrowings$0$0$3.0M$15.0M$247.0M

Latest News

Moolec Science Successfully Completes 2026 GLASO Commercial Planting Campaign in the United States ACCESS Newswire · May 14, 2026 Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period ACCESS Newswire · May 13, 2026 Moolec Science Confirms Completion of First Phase of GLASO Industrialization Following Record 2025 Campaign; Advances 2026 Sowing and Expands Into Energy Applications ACCESS Newswire · Apr 29, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$0$-2.0M$-8.0M$-9.0M$-24.0M
Investing Cash Flow$0$-138.0M$-3.0M$0$-42.0M
Financing Cash Flow$0$0$0$-2.0M$-10.0M
Net Cash Flow$0$0$1.0M$3.0M$-52.0M
Free Cash Flow$0$-2.0M$-8.0M$-9.0M$-30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-3.62
FCF Yield-861.92%
Quick Ratio0.12
Interest Coverage-0.25
Return 1Y-89.68%
Return 3Y-98.62%
Return 5Y-99.52%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
DRMADermata Therapeutics, Inc. $1.06 -0.93% -0.25 $4.26M 0.00%
ELABPMGC Holdings Inc. $3.07 -1.92% 0.00 $1.39M 0.00%
GLMD $4.63 +21.05% -0.28 $4.78M 0.00%
GTBPGT Biopharma, Inc. $6.16 +3.27% -0.06 $7.77M 0.00%
NCELNewcelX Ltd. $3.05 -2.09% 8.67 $1.37M 0.00%

About Moolec Science SA

Moolec Science SA is led by CEO Alejandro Antalich, employs 52 people, headquartered in LU, publicly traded since 2021.

Moolec Science SA (MLEC) stock trades at $2.60 with a market capitalization of $1.89M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of -0.03, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $2.60 and $23.22, and currently trades 88.8% below its 52-week high.

On profitability, Moolec Science SA generates a return on equity (ROE) of 376.84% — well above the market average, a sign of a high-quality business, return on capital employed of 33.43%, an operating margin of -2.99%, a net profit margin of -33.41%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1176.50 +0.59% JNJ Johnson & Johnson $260.45 +1.55% ABBV AbbVie Inc. $276.42 +1.47% MRK Merck & Company, Inc. Common Stock (new) $146.15 +2.64% UNH UnitedHealth Group Incorporated Common Stock (DE) $380.92 +2.69% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $660.31 +1.28% AMGN Amgen Inc. $417.07 +2.36% GILD Gilead Sciences, Inc. $150.86 +2.56% ABT Abbott Laboratories $99.23 +0.75% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides